- Home
- IGA vs KRRO Comparison
IGA vs KRRO Comparison
Compare IGA & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGA
- KRRO
- Stock Information
- Founded
- IGA 2005
- KRRO 2014
- Country
- IGA United States
- KRRO United States
- Employees
- IGA N/A
- KRRO N/A
- Industry
- IGA Investment Managers
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- IGA Finance
- KRRO Health Care
- Exchange
- IGA Nasdaq
- KRRO Nasdaq
- Market Cap
- IGA 151.6M
- KRRO 147.4M
- IPO Year
- IGA N/A
- KRRO 2019
- Fundamental
- Price
- IGA $9.94
- KRRO $33.22
- Analyst Decision
- IGA
- KRRO Strong Buy
- Analyst Count
- IGA 0
- KRRO 7
- Target Price
- IGA N/A
- KRRO $96.71
- AVG Volume (30 Days)
- IGA 42.3K
- KRRO 237.0K
- Earning Date
- IGA 01-01-0001
- KRRO 11-11-2025
- Dividend Yield
- IGA 8.93%
- KRRO N/A
- EPS Growth
- IGA N/A
- KRRO N/A
- EPS
- IGA N/A
- KRRO N/A
- Revenue
- IGA N/A
- KRRO $6,281,000.00
- Revenue This Year
- IGA N/A
- KRRO $97.27
- Revenue Next Year
- IGA N/A
- KRRO N/A
- P/E Ratio
- IGA N/A
- KRRO N/A
- Revenue Growth
- IGA N/A
- KRRO N/A
- 52 Week Low
- IGA $7.77
- KRRO $10.29
- 52 Week High
- IGA $8.88
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- IGA 55.20
- KRRO 67.72
- Support Level
- IGA $9.87
- KRRO $30.36
- Resistance Level
- IGA $10.01
- KRRO $37.03
- Average True Range (ATR)
- IGA 0.09
- KRRO 3.68
- MACD
- IGA 0.00
- KRRO -0.07
- Stochastic Oscillator
- IGA 63.70
- KRRO 77.36
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.